Beijing Science Sun Pharmaceutical Co Ltd (300485) — Net Asset Quality Index
Beijing Science Sun Pharmaceutical Co Ltd (300485) has a Net Asset Quality Index of 95.2% as of September 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥3.60 Billion minus total liabilities of CN¥171.26 Million yields net assets of CN¥3.43 Billion. A higher index indicates a stronger, lower-leverage balance sheet. See Beijing Science Sun Pharmaceutical Co Lt (300485) defensive interval to measure how many days the company can operate on defensive assets alone.
Quality Index
Net Assets
Total Assets
Total Liabilities
Beijing Science Sun Pharmaceutical Co Ltd Net Asset Quality Index Over Time (2011–2024)
This chart shows how Beijing Science Sun Pharmaceutical Co Ltd's Net Asset Quality Index has evolved across 14 annual periods from 2011 to 2024. As of September 2025, the index stands at 95.2%, representing net assets of CN¥3.43 Billion against total assets of CN¥3.60 Billion CNY. Explore 300485 operating cash flow to assess how effectively this company generates cash.
Annual Net Asset Quality Index for Beijing Science Sun Pharmaceutical Co Ltd (2011–2024)
The table below presents the year-by-year Net Asset Quality Index for Beijing Science Sun Pharmaceutical Co Ltd from 2011 to 2024, covering 14 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see Beijing Science Sun Pharmaceutical Co Lt market cap and net worth.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 95.3% | CN¥3.39 Billion | CN¥3.55 Billion | CN¥166.48 Million | ▼ -0.4 pp |
| 2023 | 95.7% | CN¥3.47 Billion | CN¥3.62 Billion | CN¥154.61 Million | ▲ +0.1 pp |
| 2022 | 95.6% | CN¥3.41 Billion | CN¥3.57 Billion | CN¥157.10 Million | ▼ -0.9 pp |
| 2021 | 96.5% | CN¥3.28 Billion | CN¥3.40 Billion | CN¥118.54 Million | ▲ +1.2 pp |
| 2020 | 95.3% | CN¥2.85 Billion | CN¥2.99 Billion | CN¥141.13 Million | ▼ -1.4 pp |
| 2019 | 96.6% | CN¥2.71 Billion | CN¥2.81 Billion | CN¥94.26 Million | ▲ +4.1 pp |
| 2018 | 92.6% | CN¥2.56 Billion | CN¥2.76 Billion | CN¥205.07 Million | ▼ -2.0 pp |
| 2017 | 94.5% | CN¥2.32 Billion | CN¥2.45 Billion | CN¥133.91 Million | ▼ -0.1 pp |
| 2016 | 94.6% | CN¥2.10 Billion | CN¥2.22 Billion | CN¥118.63 Million | ▼ -2.2 pp |
| 2015 | 96.8% | CN¥1.88 Billion | CN¥1.94 Billion | CN¥62.00 Million | ▲ +6.8 pp |
| 2014 | 90.0% | CN¥646.64 Million | CN¥718.35 Million | CN¥71.71 Million | ▼ -1.2 pp |
| 2013 | 91.3% | CN¥493.71 Million | CN¥541.04 Million | CN¥47.33 Million | ▲ +0.2 pp |
| 2012 | 91.1% | CN¥359.96 Million | CN¥395.13 Million | CN¥35.18 Million | ▲ +2.7 pp |
| 2011 | 88.4% | CN¥247.37 Million | CN¥279.77 Million | CN¥32.39 Million | — |